Sana Biotechnology (SANA) Other Non Operating Income (2020 - 2026)
Sana Biotechnology recorded quarterly Other Non Operating Income of $453000.0 in Q1 2026, down 58.74% quarter-over-quarter from $1.1 million in Q4 2025, and up 81.93% year-over-year from $249000.0 in Q1 2025.
Sana Biotechnology's Other Non Operating Income history runs 7 years deep, the most recent figure standing at $453000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 81.93% year-over-year to $453000.0; the TTM figure through Mar 2026 stood at $2.5 million (up 156.09% YoY), while the FY2025 annual figure was $2.3 million, up 151.14% from the prior year.
- Other Non Operating Income came in at $453000.0 for Q1 2026 at Sana Biotechnology, down from $1.1 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.1 million in Q4 2025 to a low of -$4.1 million in Q2 2024.
- A 5-year average of -$145588.2 and a median of -$47000.0 in 2023 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income tumbled 19900.0% in 2022 and jumped 678.72% in 2025, its largest moves.
- Sana Biotechnology's Other Non Operating Income stood at -$268000.0 in 2022, then increased by 16.42% to -$224000.0 in 2023, then soared by 162.95% to $141000.0 in 2024, then surged by 678.72% to $1.1 million in 2025, then slumped by 58.74% to $453000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $453000.0, $1.1 million, and $360000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sana Biotechnology | 890.09 Mn | 890.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 453,000.00 |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 360,000.00 |
| Jun 30, 2025 | 598,000.00 |
| Mar 31, 2025 | 249,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Sep 30, 2024 | -742,000.00 |
| Jun 30, 2024 | -4.12 Mn |
| Mar 31, 2024 | 215,000.00 |
| Dec 31, 2023 | -224,000.00 |
| Sep 30, 2023 | 303,000.00 |
| Jun 30, 2023 | -84,000.00 |
| Mar 31, 2023 | -47,000.00 |
| Dec 31, 2022 | -268,000.00 |
| Sep 30, 2022 | -106,000.00 |
| Jun 30, 2022 | -198,000.00 |
| Mar 31, 2022 | -102,000.00 |
| Dec 31, 2021 | 281,000.00 |
| Sep 30, 2021 | 10,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 13,000.00 |
| Dec 31, 2020 | 29,000.00 |
| Sep 30, 2020 | 44,000.00 |
| Jun 30, 2020 | 19,000.00 |
| Mar 31, 2020 | 5,000.00 |